Search Thermo Fisher Scientific
Search Thermo Fisher Scientific
The future of molecular profiling requires fast turnaround time for an increasingly large number of genetic biomarkers. Rapid next-generation sequencing (NGS) is helping to accelerate these critical insights by enabling test results to be available in as little as a single day.
During this workshop, see how rapid NGS is helping to facilitate swift patient enrollment into a clinical trial aiming to investigate the effectiveness of various therapeutic agents based on genetic testing results. Also, learn how NGS technology is advancing measurable residual disease (MRD) analysis by detecting low-frequency variants with high sensitivity across a broad number of genes simultaneously.
Cecilia Yeung, MD.
Associate Professor, Clinical Research Division
Fred Hutchinson Cancer Center
Medical Director, Fred Hutch CLIA Laboratories
Lauren Frady, MS, MB(ASCP)
Staff Scientist, Assay Development
Q2 Solutions
Request a quote or personal demonstration of our NGS solutions from a Thermo Fisher Representative.
For Research Use only. Not for use in diagnostic procedures.
Case number: 52968
04/24